

# Research & Innovation

## 23-24 Q1/2 Performance and Strategy Update

We are pleased to present the Q1 & 2, 2023/24 performance and strategy update for Research and Innovation

The Research and innovation team is responsible for developing and supporting a varied research portfolio, creating better opportunities for patients and staff to participate in research activity, whilst informing the provision of high-quality, evidence-based health care. Patient participation in research is mainly through studies adopted by the National Institute for Health Research (NIHR). The Trust is involved in a small number of non-adopted studies which are typically undertaken for educational purposes.


The focus for R&I in 2023/24 is to continue growing a balanced research portfolio, including attracting increased activity from commercial sponsors. The research activity will be reviewed regularly, with bi-annual reporting to the Trust board and monthly reporting to Divisional teams and research investigators.

The new R&I strategy 2022-2027, 'Research is for Everyone' sets out a clear vision to make research part of our daily business, realising the research potential in all areas of our hospitals for the benefit of patients, staff, and our community. This includes 4 key pillars: Place, Progress, People, and Partnership. This report provides an update on recruitment activity and progress against the key strategic objectives for year 1 and 2.




# Performance


### Cumulative Monthly Recruitment 2022-23 and 2023-24



### Total Participants Recruited Over the Last 5 Years




### Recruitment 22-23 & 23-24 at Q2



	FY Start	Apr	May	Jun	Jul	Aug	Sept	Oct	Nov	Dec	Jan	Feb	Mar
23-24	0	2059	2256	2463	2948	3138	3310						
22-23	0	101	289	506	727	924	1138	1466	1730	1964	2230	2490	2732
23 - 24 Target	0	270	540	810	1080	1350	1620	1890	2160	2430	2700	2970	3200

# Performance

Total Studies Open & In Follow Up by Speciality @ FY23-24 Q2



2023/24

CRN East Midlands Income

Indicative budget

£793,206.86

# Finance



2023/24 - Q1 & 2

Commercial Income

£ 31,318.23

For re-investment into future  
research capability and capacity

across SFH

Department of Health Funding

£20,000.0

To maintain research capability  
and capacity

£15,000

CRN successful bid for small  
equipment



# Patient Experience Q1-2, 23/24

Very  
professional  
and courteous



The team explained  
everything in  
detail, and I am  
helping future  
generations

Found the research  
interesting and good  
to know if will help  
people in the future



- 94% of participants agree/strongly agree their participation in research has been valued
- 90% of participants would consider taking part in research again
- For 85% of participants, it was their 1<sup>st</sup> time taking part in research.
- 100% Participants agree/strongly agree that they have been treated with courtesy and respect



Strategy Update	Progress	Place	People	Partnerships
<b>Objectives</b>	<p><b>1.1</b> Collaboration with EMCRN &amp; commercial sponsors to increase commercial research opportunities</p> <p><b>1.2</b> Streamline the set-up process for faster delivery</p>	<p><b>2.1</b> Open a new Clinical Research Facility at Kings Mill Hospital in 2023 for early phase clinical trials of new drugs, devices, and diagnostics</p> <p><b>2.2</b> Host the Nottinghamshire Mobile Research Unit to deliver place based research in our community</p>	<p><b>3.1</b> Further develop the role of the Research Academy and research opportunities for SFH staff</p> <p><b>3.2</b> Investment into our management workforce to ensure a sustainable future for research and future developments</p>	<p><b>4.1</b> Increase our academic and industry partnerships to maximise mutual benefits from collaboration</p>
<b>Risks</b>	<p><b>1.1</b> Reduction in access to novel interventions and medicines. Loss of income, reputation, and future growth as a research system partner</p> <p><b>1.2</b> Loss of repeat business, reduction in portfolio size. Failure to meet CRN targets</p>	<p><b>2.1</b> Significant impact on achieving objectives 1.1 and 4.1. Negative impact recruitment and retention and ability to fulfil our partnership with NUH for NIHR CRF bid 2026</p> <p><b>2.2</b> Unable to work efficiently across Mid Notts ICS and provide equity in access to research opportunities</p>	<p><b>3.1</b> Unable to offer the development and training opportunities to SFH staff reduce research engagement. Negative impact on staff satisfaction</p> <p><b>3.2</b> Inadequate career pathways for research staff, impact on recruitment and retention. Loss of expertise to develop R&amp;I at SFH</p>	<p><b>4.1</b> Fail to secure and sustain business from industry and showcase SFH research capabilities, linked to 1.1. Reduced access to research expertise and training for our staff. Inability to be an equitable research partner across the system</p>
<b>Progress</b>	<p>IAOCR Bronze level accreditation achieved</p> <p>Review of our front facing offer to commercial companies. Bespoke webpage dedicated to SFH hosted by CRN. Priority working with CRN Industry Lead</p> <p>68% of portfolio target for new studies met</p>	<p>Significant delays with CRF. Funding not in place</p>	<p>Training lead post in place, qualified GCP trainer</p> <p>Secured funding for Lead Academic Research NMAHP post-out to advert</p>	<p>Present at Industry Think Tank 2023. Access to select platforms to showcase our capabilities</p> <p>Early discussions CRO's regarding SFH being a priority site</p> <p>Research Communities of Practice and agreement with NTU to support training and mentorship</p>